Xu Z - Search Results

1

Development of Novel β-Carboline/Furylmalononitrile Hybrids as Type I/II Photosensitizers with Chemo-Photodynamic Therapy and Minimal Toxicity.

Xie X, Sun T, Pan H, Ji D, Xu Z, Gao G, Miao J, Wang L, Zhang Y, Liu J, Ling Y, Su X. Xie X, et al. Among authors: xu z. Mol Pharm. 2024 Jul 1;21(7):3553-3565. doi: 10.1021/acs.molpharmaceut.4c00238. Epub 2024 May 30. Mol Pharm. 2024. PMID: 38816926

2

Design and synthesis of benzylidenecyclohexenones as TrxR inhibitors displaying high anticancer activity and inducing ROS, apoptosis, and autophagy.

Qian J, Xu Z, Meng C, Liu J, Hsu PL, Li Y, Zhu W, Yang Y, Morris-Natschke SL, Lee KH, Zhang Y, Ling Y. Qian J, et al. Among authors: xu z. Eur J Med Chem. 2020 Oct 15;204:112610. doi: 10.1016/j.ejmech.2020.112610. Epub 2020 Jul 15. Eur J Med Chem. 2020. PMID: 32736231

3

Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling.

Zhu P, Qian J, Xu Z, Meng C, Liu J, Shan W, Zhu W, Wang Y, Yang Y, Zhang W, Zhang Y, Ling Y. Zhu P, et al. Among authors: xu z. J Nat Prod. 2020 Oct 23;83(10):3041-3049. doi: 10.1021/acs.jnatprod.0c00599. Epub 2020 Oct 7. J Nat Prod. 2020. PMID: 33026807

4

Efficacy of novel methylenecyclohexenone derivatives as TrxR inhibitors in suppressing the proliferation and metastasis of human cancer cells.

Meng C, Qian J, Xu Z, Liu J, Shan W, Zhu P, Zhu W, Miao J, Ling CC, Ling Y. Meng C, et al. Among authors: xu z. Bioorg Chem. 2020 Dec;105:104360. doi: 10.1016/j.bioorg.2020.104360. Epub 2020 Oct 8. Bioorg Chem. 2020. PMID: 33074118

5

Overview of piperlongumine analogues and their therapeutic potential.

Zhu P, Qian J, Xu Z, Meng C, Zhu W, Ran F, Zhang W, Zhang Y, Ling Y. Zhu P, et al. Among authors: xu z. Eur J Med Chem. 2021 Aug 5;220:113471. doi: 10.1016/j.ejmech.2021.113471. Epub 2021 Apr 21. Eur J Med Chem. 2021. PMID: 33930801 Review.

6

GSH/ROS Dual-Responsive Supramolecular Nanoparticles Based on Pillar[6]arene and Betulinic Acid Prodrug for Chemo-Chemodynamic Combination Therapy.

Zhu P, Luo W, Qian J, Meng C, Shan W, Xu Z, Zhang W, Liu X, Ling Y. Zhu P, et al. Among authors: xu z. Molecules. 2021 Sep 29;26(19):5900. doi: 10.3390/molecules26195900. Molecules. 2021. PMID: 34641443 Free PMC article.

7

A Derivative of Piperlongumine and Ligustrazine as a Potential Thioredoxin Reductase Inhibitor in Drug-Resistant Hepatocellular Carcinoma.

Qian J, Xu Z, Zhu P, Meng C, Liu Y, Shan W, He A, Gu Y, Ran F, Zhang Y, Ling Y. Qian J, et al. Among authors: xu z. J Nat Prod. 2021 Dec 24;84(12):3161-3168. doi: 10.1021/acs.jnatprod.1c00618. Epub 2021 Nov 21. J Nat Prod. 2021. PMID: 34806369

8

Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.

Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y, Zhao G, Ling Y. Ran F, et al. Among authors: xu z. Eur J Med Chem. 2022 Feb 5;229:114009. doi: 10.1016/j.ejmech.2021.114009. Epub 2021 Nov 22. Eur J Med Chem. 2022. PMID: 34839996 Review.

9

A "Double-Locked" and Enzyme/pH-Activated Theranostic Agent for Accurate Tumor Imaging and Therapy.

Luo J, Guan Z, Gao W, Wang C, Xu Z, Meng C, Liu Y, Zhang Y, Guo Q, Ling Y. Luo J, et al. Among authors: xu z. Molecules. 2022 Jan 10;27(2):425. doi: 10.3390/molecules27020425. Molecules. 2022. PMID: 35056740 Free PMC article.

10

Recent development of BTK-based dual inhibitors in the treatment of cancers.

Ran F, Liu Y, Xu Z, Meng C, Yang D, Qian J, Deng X, Zhang Y, Ling Y. Ran F, et al. Among authors: xu z. Eur J Med Chem. 2022 Apr 5;233:114232. doi: 10.1016/j.ejmech.2022.114232. Epub 2022 Feb 25. Eur J Med Chem. 2022. PMID: 35247756 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38,776 results

Search Page

Filters